Micofenolato Mofetile Accord

Mycophenolate Mofetil, the active ingredient in Micofenolato Mofetile Accord, is an antimetabolite presented as an oral tablet for oral use. It is employed to prevent acute rejection after organ transplantation and to treat lupus nephritis by suppressing the activity of T‑ and B‑lymphocytes.\n\nGNH India supplies Micofenolato Mofetile Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is an antimetabolite immunosuppressant used in several transplant‑related and autoimmune settings.\n\n- Kidney transplantation: prevents acute graft rejection.\n- Heart transplantation: reduces risk of early rejection episodes.\n- Liver transplantation: maintains graft tolerance after surgery.\n- Lupus nephritis: diminishes renal inflammation and proteinuria, improving kidney function.

Mycophenolate Mofetile Accord may cause a range of adverse reactions, from mild to serious.\n\nCommon Side Effects:\n- Nausea: mild to moderate gastrointestinal upset.\n- Diarrhea: frequent loose stools.\n- Abdominal pain: cramping or discomfort.\n- Headache: transient tension‑type pain.\n- Vomiting: occasional emesis.\n- Dyspepsia: indigestion or heartburn.\n\nSerious or Rare Side Effects:\n- Opportunistic infections: increased susceptibility to viral, fungal or bacterial pathogens.\n- Leukopenia: marked reduction in white blood cells.\n- Anemia: decreased red blood cell count leading to fatigue.\n- Lymphopenia: low lymphocyte levels compromising immunity.\n- Malignancy: rare reports of post‑transplant lymphoproliferative disorder.\n- Severe hepatic injury: elevated liver enzymes or jaundice.

Before initiating therapy, clinicians should assess baseline laboratory values and patient risk factors.\n\n- Monitor blood counts: perform regular CBC to detect leukopenia or anemia.\n- Assess renal function: adjust dose if creatinine clearance declines.\n- Screen for infections: treat active infections before starting therapy.\n- Avoid use in pregnancy: contraindicated unless benefits outweigh potential fetal risks.\n- Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil can interact with several agents, altering its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- Cyclosporine: increases nephrotoxicity risk.\n- Tacrolimus: raises mycophenolate exposure, heightening toxicity.\n- Antacids containing aluminum or magnesium: reduce oral absorption of mycophenolic acid.\n\nModerate Interactions (Monitor Closely):\n- Azathioprine: additive bone‑marrow suppression.\n- Live vaccines: heightened risk of vaccine‑derived infection.\n- Rituximab: may amplify infection susceptibility.